Is There a Safety Concern for Drug-Coated Balloons in Peripheral Arterial Disease?
Purpose of Review
Drug-coated balloons (DEB) and drug-eluting stents (DES) emerged as a tool to aid in lowering the rates of neointimal hyperplasia and target lesion restenosis following endovascular peripheral arterial disease (PAD) interventions.
Although the initial trials comparing these devices with non-drug balloons and stents showed favorable results, more recent data raised concerns regarding the mid to long-term safety of these devices.
In this review, we will discuss the evolution of endovascular therapy for PAD, with highlights regarding the recent debates on the long-term safety of the drug-coated devices for treatment of PAD.
KeywordsPeripheral arterial disease Endovascular therapy Paclitaxel Mortality
Compliance with Ethical Standards
Conflict of Interest
Mohamed M. Gad, Antonette K. Karrthik, Ahmad A Mahmoud, and Ahmed N. Mahmoud declare no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 6.Gray BH. Chapter 9b - Endovascular treatment of lower extremity arterial occlusive disease: femoropopliteal and tibial interventions. In: Hallett JW, Mills JL, Earnshaw JJ, Reekers JA, Rooke TW, editors. Comprehensive vascular and endovascular surgery. Second ed. Philadelphia: Mosby; 2009. p. 151–75.CrossRefGoogle Scholar
- 14.Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19(1):1–9.CrossRefGoogle Scholar
- 19.Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther. 2011;18(5):613–23.CrossRefGoogle Scholar
- 22.Fanelli F, Cannavale A, Corona M, Lucatelli P, Wlderk A, Salvatori FM. The “DEBELLUM”--lower limb multilevel treatment with drug eluting balloon--randomized trial: 1-year results. J Cardiovasc Surg. 2014;55(2):207–16.Google Scholar
- 30••.. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal srtery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245 Findings from the meta-analysis published by Katsanos et al. suggested an increased mortality risk associated with paclitaxel-coated devices and highlighted the lack of long-term follow-up data.CrossRefGoogle Scholar
- 32.Swedish Drug-elution Trial in Peripheral Arterial Disease (SWEDEPAD) [06/01/2019]. Available from: https://clinicaltrials.gov/ct2/show/NCT02051088. Accessed 8 June 2019.
- 33.(FDA) USFaDA. Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality - letter to health care providers 2019 [Available from: https://www.fda.gov/medical-devices/letters-health-care-providers/treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting-stents. Accessed 8 June 2019.
- 34.(FDA) USFaDA. UPDATE: Treatment of peripheral arterial disease with paclitaxel-coated balloons and paclitaxel-eluting stents potentially associated with increased mortality - letter to health care providers 2019 [Available from: https://www.fda.gov/medical-devices/letters-health-care-providers/update-treatment-peripheral-arterial-disease-paclitaxel-coated-balloons-and-paclitaxel-eluting. Accessed 8 June 2019.
- 35.Granada J. Toxicological aspects and safety profile of paclitaxel [Internet]. Linc2019.cncptdlx.com. 2019 [cited 9 June 2019]. Available from: https://linc2019.cncptdlx.com/media/1116_Juan_Fernando_Granada_Solis_22_01_2019_Room_1_-_Main_Arena_1_v1.pdf [. Accessed 8 June 2019.
- 36.Schneider P. DCBs over the long-term: are they safe for our PAD patients? Insights from IN.PACTTM DCB program [Internet]. Linc2019.cncptdlx.com. 2019 [cited 9 June 2019]. Available from: https://linc2019.cncptdlx.com/media/1128_Peter_Schneider_22_01_2019_Room_1_-_Main_Arena_1.pdf. Accessed 8 June 2019.
- 37.Dake M. Long-term safety information on paclitaxel eluting stents: insights from the Zilver PTX programme [Internet]. Linc2019.cncptdlx.com. 2019 [cited 9 June 2019]. Available from: https://linc2019.cncptdlx.com/media/1143_Michael_Dake_22_01_2019_Room_1_-_Main_Arena_1_v2.pdf [. Accessed 8 June 2019.
- 38.Drug elution in peripheral artery disease (PAD): a critical analysis from a multispecialty consortium [Internet]. 2019 [cited 9 June 2019]. Available from: https://vivaphysicians.org/vlf. Accessed 8 June 2019.
- 39.SVS announces new task force on paclitaxel safety | Society for Vascular Surgery [Internet]. Vascular.org. 2019 [cited 9 June 2019]. Available from: https://vascular.org/news-advocacy/svs-announces-new-task-force-paclitaxel-safety. Accessed 8 June 2019.
- 40.Physician and healthcare payer information | Medtronic [Internet]. Newsroom.medtronic.com. 2019 [cited 9 June 2019]. Available from: http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2387744. Accessed 8 June 2019.
- 41.Dake M, Ansel G, Jaff M, Ohki T, Saxon R, Smouse H et al. Correction to: Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery 5-Year Results of the Zilver PTX Randomized Trial. Circulation. 2019;139(8). https://doi.org/10.1161/CIR.0000000000000657.
- 42•.. Schneider PA, Laird JR, Doros G, Gao Q, Ansel G, Brodmann M, et al. Correction mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon. Journal of the American College of Cardiology. 2019;73(20):2643 Schneider et al. performed an independent, individual patient-level meta-analysis that showed no statistically significant increase in mortality risk conflicting with prior results reported by Katsanos et al. and igniting further debate about the safety of paclitaxel-coated devices.CrossRefGoogle Scholar
- 45.Secemsky EA, Kundi H, Weinberg I, Jaff MR, Krawisz A, Parikh SA, et al. Association of durvival with femoropopliteal artery revascularization with drug-coated devices. JAMA Cardiol. 2019.Google Scholar
- 51.Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231–8.CrossRefGoogle Scholar
- 52.Tepe G, Laird J, Schneider P, Brodmann M, Krishnan P, Micari A, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502.CrossRefGoogle Scholar